Biograil ApS
Biograil ApS

Biograil ApS

Measured by AhrefsDR15Ahrefs DR: 15/100. Bottom 25%. Measured by Ahrefs. Median 44.Measured by StartupHub.aieDR8Effective DR: 8/100. Bottom 25%. Measured by StartupHub.ai. Median 68.Measured by StartupHub.aiAgent39Agent Readiness: 39/100. Below median. Measured by StartupHub.ai. Median 41.Measured by Google PageSpeedSpeed61Site Speed: 61/100. Below median. Measured by Google PageSpeed. Median 62.

Biograil develops oral devices to deliver therapeutics that would otherwise require injections, leveraging its proprietary BIONDD® technology to transform injectable pharmaceutical products into convenient oral capsules.

Website

About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules

2019ActiveRoskilde, Denmark

About

Biograil is a pre-clinical stage pharmaceutical company based in Roskilde, Denmark, focused on transforming injectable medicines into convenient oral capsules. Their proprietary BIONDD® platform enables oral delivery of biologics, including peptides, antibodies, and RNAs, which are currently administered via injection. The technology uses a small, easy-to-swallow capsule that mechanically delivers active therapeutic macromolecules into the stomach mucosal wall for systemic absorption.

Competitors & Alternatives (6)

Similar companies

EP
EyeGate Pharmaceuticals
EyeGate Pharmaceuticals

Clinical-stage specialty pharmaceutical company developing therapeutics and drug delivery systems for ophthalmic diseases.

Shares Biotech, MedTech

B
BeiGene
BeiGene

A global oncology company developing and commercializing innovative cancer treatments.

Shares Biotech, MedTech

N
NewLimit
NewLimit

NewLimit is developing epigenetic therapies to extend human healthspan by reprogramming aging cells.

Shares Biotech, HealthTech

A
Alector
Alector

Biotechnology company developing immuno-neurology therapies for neurodegenerative diseases.

Shares Biotech, MedTech

P
PhosPrint
PhosPrint

Biotech startup developing laser bioprinting systems for regenerative medicine and biosensor applications.

Shares Biotech, MedTech

S
Seevix
Seevix

Seevix Material Sciences develops and produces SVX, a proprietary spider silk protein, for various industrial and medical applications.

Shares Biotech, Medical Devices

Key facts

Website
biograil.com
Headquarters
Roskilde, Denmark
Founded
2019
Total funding
$37M (Growth)
Business model
B2B

Funding rounds

Funding rounds raised by Biograil ApS
DateRoundAmountLead investors
1 Nov 2026Growth$22MVerve Ventures
1 Jul 2025Series B$9MVerve Ventures
17 Feb 2022Seed$3M
15 Jan 2020Seed$3MHigh-Tech Gründerfonds

Tech stack

Detected on biograil.com, last scanned 4 Nov 2026.

Frontend
jQuery, Bootstrap
CMS / Builders
WordPress
Email provider
Microsoft 365
Cookie consent
iubenda
Video / media
YouTube
Run your own scan

Biograil ApS scores 15. Does yours?

That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.

Add first review

Frequently asked

Is Biograil ApS trustworthy and reputable?

StartupHub's Data Trust & Reputation score for Biograil ApS is 84 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has Biograil ApS raised?

Biograil ApS has raised a total of $37M in funding. The most recent round on record is Growth.

Public record

SEC filings, insider activity, nonprofit links and pay benchmarks for Biograil ApS